Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Stefano Fiori et al.|The Lancet Haematology|2025Cited by 6
Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)Enrico Tiacci, Monia Capponi, Andrea Bernardelli et al.|HemaSphere|2025Cited by 1
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trialRiccardo Moia, Monica Balzarotti, Mohammad Almasri et al.|Blood Advances|2026Cited by 0